Steven E. Kahn, MB, ChB, accepted the Banting Medal for Scientific Achievement at the Scientific Sessions in Chicago. His lab identified a hyperbolic relationship between beta cell response and insulin sensitivity in the early 1990s. In his award lecture, he discussed how this dynamic fits into pathogenesis and progression of type 2 diabetes.
New and revised recommendations for the care of people living with diabetes cover glucose-lowering pharmacotherapy, diabetes, technology, population health considerations, and more. Naushira Pandya, MD, CMD, gave an overview of the updated Standards of Care for older adults with diabetes.
CORRECTION: Subodh Verma, MD, PhD, FRCSC, and others explained how semaglutide can change the trajectory of disease in individuals with type 2 diabetes and peripheral artery disease.
Experts discussed findings from two phase 3 studies that evaluated the efficacy of combined treatment with an amylin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist in inducing weight loss in individuals living with obesity or overweight.
Lara Dugas, PhD, MPH, and other panelists will examine the impact of common misconceptions and summarize new insights about the dynamics of muscle mass, energy expenditure, and individual metabolism.
Pediatric endocrinologist and physician-scientist Mustafa Tosur, MD, FAAP, will open a symposium on trending topics and smart solutions for diagnosing and managing diabetes in children, adolescents, and young adults.
Panelists, including Savitha Subramanian, MD, will detail the latest therapies for severe hypertriglyceridemia, the genetics of hypertriglyceridemia, and the dynamics of hypertriglyceridemia-induced acute pancreatitis
Speakers shared evidence of population-wide weight loss and improved use of weight-related treatment. Mark Gritz, PhD, said the goal was affordable care delivery that could be implemented broadly.
Alison Evert, MS, RDN, CDCES, discussed three key components of diabetes nutrition therapy in her award lecture: research, recommendations, and real-world experiences.
Julio Rosenstock, MD, shared data from ACHIEVE-1 that show orforglipron led to reductions in A1C and meaningful weight loss as monotherapy in drug-naïve type 2 diabetes with inadequate glycemic management.